Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell
CA 2346218 A1 · Owner: Hansen, Christina Veggerby · Inventors: Florio, Walter; Rosenkrands, Ida; Hansen, Christina Veggerby
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to substantially pure polypeptides which has a , sequence identity of at least 80 % to an amino acid sequence disclosed or , which is a subsequence of at least 6 amino acids thereof preferably a B- or T-, cell epitope of the polypeptides disclosed. The polypeptide or the subsequence thereof has at least one of nine properties. The use of the disclosed polypeptides in medicine is disclosed, preferably as vaccine or diagnostic agents relating to virulent <i>Mycobacterium</i>. The invention further relates to the nucleotide sequences disclosed and the nucleotide sequences encoding the disclosed polypeptides. Medical and non-medical use of the nucleotide …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 8, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 8, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 8, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.